1. Home
  2. STRW vs ACOG Comparison

STRW vs ACOG Comparison

Compare STRW & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STRW

Strawberry Fields REIT Inc.

SELL

Current Price

$12.26

Market Cap

197.5M

Sector

Real Estate

ML Signal

SELL

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

SELL

Current Price

$7.94

Market Cap

180.5M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
STRW
ACOG
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
197.5M
180.5M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
STRW
ACOG
Price
$12.26
$7.94
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$15.50
★ $18.20
AVG Volume (30 Days)
39.1K
★ 102.0K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
★ 5.55%
N/A
EPS Growth
5.26
★ 41.58
EPS
★ 0.06
N/A
Revenue
★ $154,999,000.00
$10,220,275.00
Revenue This Year
$3.46
$162.31
Revenue Next Year
$5.82
$86.08
P/E Ratio
$207.33
★ N/A
Revenue Growth
★ 32.41
N/A
52 Week Low
$11.58
$4.50
52 Week High
$14.75
$10.14

Technical Indicators

Market Signals
Indicator
STRW
ACOG
Relative Strength Index (RSI) 45.47 39.42
Support Level $12.14 $7.69
Resistance Level $13.33 $9.21
Average True Range (ATR) 0.55 0.51
MACD 0.01 -0.06
Stochastic Oscillator 32.28 11.59

Price Performance

Historical Comparison
STRW
ACOG

About STRW Strawberry Fields REIT Inc.

Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: